Furthermore, SAR405838(MI-77301) and APG-115 are all spirooxindole-based MDM2 inhibitors developed by Wang Shaomeng’s research group.387,1059 APG-115 is designed to overcome stability-related issues observed in SAR405838.1054,1060 APG-115 can strongly bind with MDM2 protein, and has good chemical stability and excellent oral pharmacokinetic parameters.387 A phase I study of SAR405838 in patients with advanced cancer has been completed (NCT01636479), but no result has been posted. The gene discussed is MDM2; the disease is cancer.